Arbutus Biopharma Had Cash, Cash Equivalents And Investments In Marketable Securities Of $163.5M, With Cash Runway Into Q1 2025; 2023 Net Cash Burn To Range From Between $90M-$95M
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma reported cash, cash equivalents, and investments in marketable securities of $163.5M, providing a cash runway into Q1 2025. The company expects its 2023 net cash burn to range between $90M-$95M.
August 04, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arbutus Biopharma's strong cash position and extended cash runway into Q1 2025 may provide stability. However, the projected net cash burn of $90M-$95M in 2023 could be a concern for investors.
Arbutus Biopharma's strong cash position indicates financial stability, which is generally positive for the stock. However, the projected high cash burn in 2023 could indicate potential financial risks, which may negatively impact the stock. Therefore, the overall short-term impact is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100